ID   ORF3B_SARS2             Reviewed;          22 AA.
AC   P0DTF1;
DT   10-FEB-2021, integrated into UniProtKB/Swiss-Prot.
DT   10-FEB-2021, sequence version 1.
DT   08-NOV-2023, entry version 9.
DE   RecName: Full=Putative ORF3b protein {ECO:0000305|PubMed:32854725};
DE            Short=ORF3b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
RN   [2]
RX   PubMed=32854725; DOI=10.1186/s12985-020-01402-1;
RA   Michel C.J., Mayer C., Poch O., Thompson J.D.;
RT   "Characterization of accessory genes in coronavirus genomes.";
RL   Virol. J. 17:131-131(2020).
RN   [3]
RX   PubMed=32807944; DOI=10.1038/s41590-020-0773-7;
RA   Hachim A., Kavian N., Cohen C.A., Chin A.W.H., Chu D.K.W., Mok C.K.P.,
RA   Tsang O.T.Y., Yeung Y.C., Perera R.A.P.M., Poon L.L.M., Peiris J.S.M.,
RA   Valkenburg S.A.;
RT   "ORF8 and ORF3b antibodies are accurate serological markers of early and
RT   late SARS-CoV-2 infection.";
RL   Nat. Immunol. 21:1293-1301(2020).
RN   [4]
RX   PubMed=32941788; DOI=10.1016/j.celrep.2020.108185;
RG   USFQ-COVID19 Consortium;
RA   Konno Y., Kimura I., Uriu K., Fukushi M., Irie T., Koyanagi Y., Sauter D.,
RA   Gifford R.J., Nakagawa S., Sato K.;
RT   "SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is
RT   Increased by a Naturally Occurring Elongation Variant.";
RL   Cell Rep. 32:108185-108185(2020).
RN   [5]
RX   PubMed=33976134; DOI=10.1038/s41467-021-22905-7;
RA   Jungreis I., Sealfon R., Kellis M.;
RT   "SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44
RT   Sarbecovirus genomes.";
RL   Nat. Commun. 12:2642-2642(2021).
CC   -!- FUNCTION: Acts as an interferon antagonist when expressed ex vivo.
CC       {ECO:0000269|PubMed:32941788}.
CC       P0DTF1; P52954: LBX1; Xeno; NbExp=3; IntAct=EBI-26953451, EBI-20141748;
CC       P0DTF1; Q9GZY8: MFF; Xeno; NbExp=3; IntAct=EBI-26953451, EBI-11420856;
CC   -!- MISCELLANEOUS: SARS-CoV-2 ORF3b is homologous to SARS-CoV ORF3b,
CC       although the proposed protein is much shorter due to the presence of
CC       premature stop codons (Probable). Elicits strong specific antibody
CC       response (PubMed:32807944). {ECO:0000269|PubMed:32807944,
CC       ECO:0000305|PubMed:32854725}.
CC   -!- CAUTION: Product of a dubious CDS prediction.
CC       {ECO:0000303|PubMed:33976134}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   IntAct; P0DTF1; 34.
DR   MINT; P0DTF1; -.
DR   PRO; PR:P0DTF1; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0019049; P:mitigation of host antiviral defense response; IEA:UniProtKB-KW.
PE   5: Uncertain;
KW   Interferon antiviral system evasion; Reference proteome.
FT   CHAIN           1..22
FT                   /note="Putative ORF3b protein"
FT                   /id="PRO_0000452089"
SQ   SEQUENCE   22 AA;  2457 MW;  53D80549C8F78A22 CRC64;